This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.



 M Bio Technology Inc. 【Field/Business】
Medical care/Diagnosis/Medical equipment/Healthcare
Pharmaceutical/Drug Discovery
Drug discovery support/Contract service
last update:2016/12/27
Profile
Delegates Kazuhiro Matsuda
Incorporated January  5 , 2005
Paid in Capital 186 Million yen  
Employees 2
Address 2-1-3-1103 Fukasawa, Setagaya-ku TOKYO
〒158-0081
TEL/FAX 090-8486-5727 / 03-3705-5230
URL
http://www.mbiotech.org/English/company4.html
Attachment
Mission/Background
M Bio Technology Inc. is the research-and-development type venture business established on January 5, 2005.

M Bio Technology Inc. is focusing on the diagnosis, therapeutic and prevention with mycoplasma infectious diseases.

Mycoplasma infection cause not only pneumonia but vasculitis based asthma, arthritis, nephritis, meningitis, encephalitis, arteritis, dermatitis, etc., and furthre, autoimmune diseases, rheumatic disease and a nervous system disorders, innflammatory diseases.

M Bio Technology Inc. is aiming for bussiness development on the mycoplasma lipid-antigen technologies.The diagnosis and drug design to the pathogenic microbe using the synthesized lipid antigen are world's first platform technology, and, would like to explore mutual business opportunities, in the field of diagnostics and vaccines.

We make global development of the plan with the open innovation, and wish joint development, a business tie-up, and the information and support relevant to a finance.
Technology & Business
The mycoplasma vaccine and diagnostics using the synthesized mycoplasma-specific glycolipid antigen are world's first platform technology. The core technology is structural anlysis and chemical synthesis of mycoplasma lipid-antigens.

The novel diagnostic method can measure IgM, IgG, and IgA, separately. The cause of incurable disease, mycoplasma infection, can be found, and the medical treatment which can remove the real cause.

Further, the companion diagnostic product is applicable to drug design, and becomes an important key of the morbidity elucidation of mycoplasma infection, and curative medicine development, such as a vaccine, an antibody drug, and an immune therapy.

We are looking for alliance partners for IND, preclinical〜PhI/PhII, PhIII and marketing, also for $ 20M investment or fund for preclinical〜PhI/PhII .
Products & Service
Products & Service Name
Stage
Outline
Milestone
Precision Preventative Medicine for Mycoplasma Infectious Diseases (MID)
Service/Marketing
It becomes possible to find Mycoplasma Infectious Diseases (MID) at an early stage, and to treat a cause of a disease curatively
We are seeking partnering opportunities to create global network for the advanced medicine worldwide.
Vaccine for Mycoplasma Infectious Diseases (MID)
Preclinical
Simplest component vaccine, whose component are chemically-synthesized lipid-antigen
We are seeking partners of maycoplasma vaccine in development worldwide. IND, preclinical〜PhI/PhII, PhIII and marketing.
Therapeutic antibodies, adjuvant, and new drug design.
Service/Marketing
PhIV differential diagnosis of side effects (interstitial pneumonia, Stevens-Johnson syndrome) .
We are seeking partners of new therapeutic drugs with pharmaceutical industries using mycoplasma companion diagnostics.
Innovative companion diagnostics for Mycoplasma Infectious Diseases (MID)
Service/Marketing


Drug re-positioning based on the innovative diagnostics for Mycoplasma Infectious Diseases (MID)
Phase2/3


Highlights
The patents of mycoplasma vaccine have been approved worldwide.
The patents of mycoplasma lipid antigens was registered in Japan, US, Australia etc..

The POC of the mycoplasma vaccine has been accumulated.

The advanced precision medicine using the new diagnostics has been proposed since April, 2012.
The precise mesurement of antibodies in sera started in alliance with diagnostics and clinics.
It becomes possible to discover mycoplasma infectious diseases at an early stage, and to treat.
Alliance strategy
Novel companion diagnostics for mycoplasma infectious disease
・Proposal of a mycoplasma infection medical package to diagnostics, clinics and hospitals
・We are seeking partnering opportunities in and create global network for the therapy of mycoplasma infectious diseases.
Mycoplasma vaccine development project
・We are seeking a co-development and marketing partner of maycoplasma vaccine in the pharmaceutical companies and biotech industries worldwide. preclinical〜PhI/PhII, PhIII and marketing.
Hot news
The advanced medicine using a new diagnostic product has been proposed since April, 2012.
The laboratory located in Chibadai Inovation Plaza colaborating with Chiba university.

Antigens: Lipids, Kazuhiro Matsuda, Encyclopedia of Life Sciences. John Wiley & Sons, Ltd http://www.els.net

K. Matsuda, A novel therapeutic strategy for mycoplasma infectious diseases. Personalized Medicine Universe 4 : 32-39 (2015)

Cluster
Metropolitan Bio Network Japan
Japan Bioindustry Association
http://www.cluster.gr.jp/relation/data/brochure_e.html
http://www.noastec.jp/biocluster/english/index.html
-
-
http://www.hobia.jp/english/
-
-
-
-
-
-
http://www.jba.or.jp/syutokenbio/
http://www.jba.or.jp/pc/en/
http://www.tsukuba-tci.co.jp/
http://www.kazusa.or.jp/e/index.html
-
http://www.fuji-pvc.jp/english/index.aspx
-
-
-
-
http://www.fuji-pvc.jp/english/index.aspx
-
-
-
http://kinkibio.com/english/01.html
-
http://www.astem.or.jp/english/
http://www.osaka.cci.or.jp/e/index.html
-
http://www.ibri-kobe.org/english/index.html
-
-
-
-
http://www.joho-shimane.or.jp/english.html
-
http://www.hiwave.or.jp/HAPEE/english/index.html
-
-
-
-
-
-
-
-
-
-
-
-
-
http://www.smrj.go.jp/english/index.html
-
-
-
-
-
-
-
-
-
-
-
-

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.